15 January 2013 - RNAi therapeutics company Alnylam Pharmaceuticals Inc (NasdaqGS :ALNY) revealed on Monday plans to commence an $125m underwritten public offering of shares of its common stock.

The company proposes to sell all of the shares in the offering.

Additionally, the underwriters have been provided with a 30-day option to purchase up to an additional 15% of the number of shares sold to cover over-allotments, if any.

JP Morgan Securities LLC and Morgan Stanley & Co LLC are acting as joint book-running managers and representatives of the underwriters for the offering.

Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.